Legal status · United States
Is Ruxolitinib legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Yes. Ruxolitinib is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Ruxolitinib in the United States at a glance
| Classification | FDA-approved, prescription only |
|---|---|
| Note | Jakafi (oral) and Opzelura (cream), both Incyte. Opzelura carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Jakafi does not carry a boxed warning but is labelled with warnings for cytopenias, infection, non-melanoma skin cancer, lipid elevations, MACE, thrombosis and secondary malignancies. |
| FDA approval status | FDA-approved as Jakafi for myelofibrosis, polycythaemia vera and steroid-refractory acute and chronic graft-versus-host disease, and as Opzelura cream for atopic dermatitis and non-segmental vitiligo. Not approved for ageing, frailty or any senescence indication, and not in a registered trial for one. |
| Human studies cited | 2 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Ruxolitinib profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FDA has approved Ruxolitinib for at least one labeled indication, so a pharmaceutical-grade product exists in the United States and is dispensed on prescription.
- 02
Approval is indication-specific. Uses outside the label are a clinical decision for a prescriber, not something the approval itself authorizes.
- 03
Unlicensed online vials, including those labeled "research use only", are not the approved product and are not covered by the approval.
What Ruxolitinib is
An approved JAK1 and JAK2 inhibitor that suppressed the senescence-associated secretory phenotype and improved physical function in aged mice. Its entire human evidence base is in myelofibrosis, where it shrinks spleens; the topical form carries a boxed warning for serious infections, mortality, malignancy, cardiovascular events and thrombosis.
Ruxolitinib is the clearest example of a senomorphic rather than a senolytic. A senolytic kills senescent cells.
Mechanism: Ruxolitinib inhibits Janus kinase 1 and Janus kinase 2, the intracellular kinases that transduce signals from a large family of cytokine receptors through the STAT transcription factors. Much of the senescence-associated secretory phenotype is produced and reinforced through that pathway, so blocking JAK1 and JAK2 quietens the secretions without killing the senescent cell.
Regulatory history: FDA-approved as Jakafi for myelofibrosis, polycythaemia vera and steroid-refractory acute and chronic graft-versus-host disease, and as Opzelura cream for atopic dermatitis and non-segmental vitiligo. Not approved for ageing, frailty or any senescence indication, and not in a registered trial for one.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Ruxolitinib at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Ruxolitinib in other countries
Frequently asked questions
Is Ruxolitinib legal in the United States?
Yes. Ruxolitinib is an approved medicine in the United States, classified as "FDA-approved, prescription only". Approval covers its labeled indication and it is supplied on prescription, not over the counter. Products labeled "research use only" fall outside that approval and the label does not make human use lawful. On the evidence, 2 human studies are cited on its profile. Note: Jakafi (oral) and Opzelura (cream), both Incyte. Opzelura carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Jakafi does not carry a boxed warning but is labelled with warnings for cytopenias, infection, non-melanoma skin cancer, lipid elevations, MACE, thrombosis and secondary malignancies.
Can I buy Ruxolitinib in the United States?
Only with a prescription. Ruxolitinib is classified as "FDA-approved, prescription only" in the United States, so it is dispensed by pharmacies against a prescription for its approved indication. Buying it from unlicensed online sellers or as a "research chemical" is outside that system and carries no regulatory protection. Note: Jakafi (oral) and Opzelura (cream), both Incyte. Opzelura carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. Jakafi does not carry a boxed warning but is labelled with warnings for cytopenias, infection, non-melanoma skin cancer, lipid elevations, MACE, thrombosis and secondary malignancies.
Is Ruxolitinib FDA approved?
Yes. FDA status: FDA-approved as Jakafi for myelofibrosis, polycythaemia vera and steroid-refractory acute and chronic graft-versus-host disease, and as Opzelura cream for atopic dermatitis and non-segmental vitiligo. Not approved for ageing, frailty or any senescence indication, and not in a registered trial for one.. Current US classification: "FDA-approved, prescription only". On the evidence, 2 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Ruxolitinib live on its compound profile.
Ruxolitinib profileThis page is general information about the regulatory status of Ruxolitinib in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.